Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Adjuvant Therapy for Resected Biliary Tract Cancer

Publication Date: March 11, 2019

Last Updated: December 15, 2022

Treatment

Patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. ( EB , H , H , M )

Qualifying statements:

In the BILCAP phase III randomized controlled trial, capecitabine was delivered at a dose of 1250 mg/m² twice/day on treatment day 1 to 14 of a 3-weekly cycle for 24 weeks (8 cycles).
The Expert Panel agrees that the recommended dose of capecitabine may be determined by institutional and regional practices.

3336

Overview

Title

Adjuvant Therapy for Resected Biliary Tract Cancer

Authoring Organization